Moreover, HIV infection has been consistently associated with increased numbers of activated uninfected bystander CD4 and CD8 T lymphocytes [44], [45], and this may pose a serious challenge in developing LtxA for an HIV therapeutic drug as these cells are likely more susceptible to LtxA. The gene discussed is CD8A; the disease is HIV infectious disease.